The Use of Antifactor Xa Assays in a Comprehensive Pediatric Extracorporeal Membrane Oxygenation Anticoagulation Protocol is Associated with Increased Survival and Significant Blood Product Cost-Savings

Abstract

We augmented our standard extracorporeal membrane oxygenation laboratory protocol to include antifactor Xa assays, thromboelastography, and antithrombin measurements. We performed a retrospective chart review to determine outcomes for patients placed on extracorporeal membrane oxygenation (ECMO) prior to and after the initiation of our anticoagulation laboratory protocol. A total of 663 consecutive ECMO runs were evaluated from January 1, 2007 to June 30, 2018. Of these patients, 252 were on ECMO prior to initiation of the anticoagulation laboratory protocol on September 1, 2011, and 411 patients were on ECMO after initiation of the protocol. There were no major changes to our extracorporeal membrane oxygenation circuit or changes to our transfusion threshold during this continuous study period. Transfusion utilization data revealed statistically significant decreases in almost all blood components, and a savings in blood component inflation-adjusted acquisition costs of 31% bringing total blood product cost-savings to $309,905 per year. In addition, there was an increase in survival to hospital discharge from 45 to 56% associated with the initiation of the protocol (p = 0.004). Our data indicate that implementation of a standardized ECMO anticoagulation protocol, which titrates unfractionated heparin infusions based on antifactor Xa assays, is associated with reduced blood product utilization, significant blood product cost savings, and increased patient survival. Future prospective evaluation is needed to establish an antifactor Xa assay-driven ECMO anticoagulation strategy as both clinically superior and cost-effective.

Keywords

antifactor Xa - antithrombin - extracorporeal membrane oxygenation - hemorrhagic - heparin

Publication History

Received: 13 November 2020

Accepted: 17 February 2021

Article published online:
01 April 2021

• References

• 1 Barbaro RP, Paden ML, Guner YS. et al; ELSO member centers. Pediatric extracorporeal life support organization registry international report 2016. ASAIO J 2017; 63 (04) 456-463
• 2 Zangrillo A, Landoni G, Biondi-Zoccai G. et al. A meta-analysis of complications and mortality of extracorporeal membrane oxygenation. Crit Care Resusc 2013; 15 (03) 172-178
• 3 Thomas J, Kostousov V, Teruya J. Bleeding and thrombotic complications in the use of extracorporeal membrane oxygenation. Semin Thromb Hemost 2018; 44 (01) 20-29
• 4 Dalton HJ, Garcia-Filion P, Holubkov R. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network. Association of bleeding and thrombosis with outcome in extracorporeal life support. Pediatr Crit Care Med 2015; 16 (02) 167-174
• 5 Cashen K, Meert K, Dalton HJ. Platelet count and function during pediatric extracorporeal membrane oxygenation. Semin Thromb Hemost 2020; 46 (03) 357-365
• 6 Andrews J, Winkler AM. Challenges with navigating the precarious hemostatic balance during extracorporeal life support: implications for coagulation and transfusion management. Transfus Med Rev 2016; 30 (04) 223-229
• 7 Lansink-Hartgring AO, Hoffmann R, van den Bergh W, de Vries A. Changes in red blood cell properties and platelet function during extracorporeal membrane oxygenation. J Clin Med 2020; 9 (04) 1168
• 8 Muszynski JA, Reeder RW, Hall MW. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network (CPCCRN). RBC transfusion practice in pediatric extracorporeal membrane oxygenation support. Crit Care Med 2018; 46 (06) e552-e559
• 9 Lequier L, Annich G, Al-Ibraham O. et al. ELSO anticoagulation guideline. The Extracorporeal Life Support Organization; 2014
• 10 Smith A, Hardison D, Bridges B, Pietsch J. Red blood cell transfusion volume and mortality among patients receiving extracorporeal membrane oxygenation. Perfusion 2013; 28 (01) 54-60
• 11 Chlebowski MM, Baltagi S, Carlson M, Levy JH, Spinella PC. Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO. Critical care (London) 2020; 24 (01) 19
• 12 Saini A, Spinella PC. Management of anticoagulation and hemostasis for pediatric extracorporeal membrane oxygenation. Clin Lab Med 2014; 34 (03) 655-673
• 13 Northrop MS, Sidonio RF, Phillips SE. et al. The use of an extracorporeal membrane oxygenation anticoagulation laboratory protocol is associated with decreased blood product use, decreased hemorrhagic complications, and increased circuit life. Pediatr Crit Care Med 2015; 16 (01) 66-74
• 14 US Bureau of Labor Statistics. 2016 Consumer price index. Accessed October 1, 2020 at: https://www.bls.gov/cpi/
• 15 Hutt Centeno E, Militello M, Gomes MP. Anti-Xa assays: what is their role today in antithrombotic therapy?. Cleve Clin J Med 2019; 86 (06) 417-425
• 16 Bembea MM, Annich G, Rycus P, Oldenburg G, Berkowitz I, Pronovost P. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey. Pediatr Crit Care Med 2013; 14 (02) e77-e84
• 17 O'Meara LC, Alten JA, Goldberg KG. et al. Anti-xa directed protocol for anticoagulation management in children supported with extracorporeal membrane oxygenation. ASAIO J 2015; 61 (03) 339-344
• 18 Liveris A, Bello RA, Friedmann P. et al. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med 2014; 15 (02) e72-e79
• 19 Hattersley PG. Activated coagulation time of whole blood. JAMA 1966; 196 (05) 436-440
• 20 Baird CW, Zurakowski D, Robinson B. et al. Anticoagulation and pediatric extracorporeal membrane oxygenation: impact of activated clotting time and heparin dose on survival. Ann Thorac Surg 2007; 83 (03) 912-919 , discussion 919–920
• 21 Bembea MM, Schwartz JM, Shah N. et al. Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation. ASAIO J 2013; 59 (01) 63-68
• 22 Khaja WA, Bilen O, Lukner RB, Edwards R, Teruya J. Evaluation of heparin assay for coagulation management in newborns undergoing ECMO. Am J Clin Pathol 2010; 134 (06) 950-954
• 23 Bridges BC, Ranucci M, Lequier LL. Anticoagulation and disorders of hemostasis. In: Brogan TV, Lequier L, Lorusso R, MacLaren G, Peek G. eds. Extracorporeal Life Support: The ELSO Red Book. Ann Arbor, MI: Extracorporeal Life Support Organization; 2017: 93-104
• 24 Maul TM, Wolff EL, Kuch BA, Rosendorff A, Morell VO, Wearden PD. Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med 2012; 13 (06) e363-e371
• 25 Teruya J. Coagulation tests affected by acute phase reactants such as CRP and Factor VIII. Paper presented at: International Conference on Hematology and Blood Disorders; Research Triangle Park, NC USA. Accessed September 23 to 25, 2013 at: https://www.elso.org/resources/guidelines.aspx
• 26 Sawyer AA, Wise L, Ghosh S, Bhatia J, Stansfield BK. Comparison of transfusion thresholds during neonatal extracorporeal membrane oxygenation. Transfusion 2017; 57 (09) 2115-2120
• 27 Cahill CM, Blumberg N, Schmidt AE. et al. Implementation of a standardized transfusion protocol for cardiac patients treated with venoarterial extracorporeal membrane oxygenation is associated with decreased blood component utilization and may improve clinical outcome. Anesth Analg 2018; 126 (04) 1262-1267
• 28 Shander A, Hofmann A, Gombotz H, Theusinger OM, Spahn DR. Estimating the cost of blood: past, present, and future directions. Best Pract Res Clin Anaesthesiol 2007; 21 (02) 271-289
• 29 Shander A, Ozawa S, Hofmann A. Activity-based costs of plasma transfusions in medical and surgical inpatients at a US hospital. Vox Sang 2016; 111 (01) 55-61